Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PLUR Catalyst Timeline
Dated clinical, regulatory and corporate events for Pluri Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Pluri Inc.
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How PLUR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PLX-PAD BiologicsCompletedNCT03006770 | Critical Limb Ischemia (CLI) | Phase 3 | COMPLETED | 213 | Apr 20, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every PLUR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| PLX-PAD | muscle injury following arthroplasty for hip fracture | Phase 3 | 2022-07-13 | 3.2kg from reference (week 6) to week 26 compared to 1.3kg in the placebo group, a 2kg difference (p=0.047); 5.01kg from reference (week 6) to week 52 compared to 0.86kg in the placebo group, a 4kg difference (p=0.0022); 2.3kg from reference (week 6) to week 26 compared to 0.51kg in the placebo group, a 1.8kg difference (p=0.073); 3.3kg from reference (week 6) to week 52 compared to a decrease of 0.7kg in the placebo group, a 4kg difference (p=0.0046); 296 meters versus only 266 meters in placebo treated patients in the 6-minute walk testRead More | Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture SurgeryRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Manieu Alexandre WeinsteinDirector, 10% Owner | BuyOffering | 833,334 2,083,334 held | $1.50 | 10/23/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PLUR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PLUR for Q3 2026. | ||||
Ownership Trends
PLUR Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How PLUR ranks across every disease it competes in
PLUR News
Pluri CEO Letter: Turning Our Cell Technology and Experience into Commercial Opportunity
Pluri Inc. is advancing its commercial strategy by leveraging over two decades of cell technology and clinical experience. The company has formed a strategic partnership with ZEO ScientifiX to penetrate the U.S. regenerative medicine market. Additionally, Pluri has successfully completed a Phase I clinical trial for PLX-PAD cells and has improved its financial position by transferring its European Investment Bank loan.
Read more →Pluri Adds ISO 9001 and ISO 13485 Certifications to Support PluriCDMO Commercial Expansion
Pluri Inc. announced that its PluriCDMO business has received ISO 9001:2015 and ISO 13485:2016 certifications. These certifications will enhance its quality management systems and support its efforts to engage more customers in the life sciences sector. CEO Yaky Yanay emphasized the importance of quality systems for customer partnerships.
Read more →Pluri to Host Investor Conference Calls to Discuss Updates and Strategic Developments
Pluri Inc. will host online investor conference calls on October 29, 2026. CEO Yaky Yanay and Chairman Alejandro Weinstein will provide updates on company developments. The sessions will be conducted in Hebrew at 11 am Israel time and in English at 8:30 am Eastern Time.
Read more →Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine
Pluri Inc. and ZEO ScientifiX have formed a strategic partnership to enhance U.S. manufacturing and commercialization in regenerative medicine. ZEO contributes its established biologics business and physician relationships, while Pluri offers its expertise in cell-based product development. The collaboration aims to broaden product offerings and strengthen clinical programs, with Pluri acquiring 50% ownership of ZEO.
Read more →Pluri Chairman and Active Investor Alejandro Weinstein to Acquire EIB Loan, in Strong Vote of Confidence in the Company
Pluri Inc. announced that Chairman Alejandro Weinstein will acquire its loan from the European Investment Bank. This move transfers a significant financial obligation to Weinstein, allowing Pluri to negotiate revised loan terms. Weinstein expressed confidence in Pluri's technology and future, emphasizing this as a step towards reshaping the company for growth in regenerative medicine.
Read more →Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor
Pluri Inc. has announced a registered direct offering and concurrent private placement, raising approximately $3.3 million by selling 2,228,940 common shares at $1.50 each. The offering is expected to close on August 28, 2026, and proceeds will be used for working capital. The company is also issuing unregistered warrants with an exercise price of $1.65.
Read more →Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment
Pluri Inc. announced that its subsidiary, Ever After Foods, has acquired Fishway, a Belgium-based biotechnology company specializing in aquatic cell biology. This acquisition, along with a $2 million strategic investment, aims to enhance Ever After Foods' cultivated-protein platform and expand its capabilities in the European market. The move is expected to strengthen the company's ability to support scalable production for food and ingredient companies.
Read more →Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK
Pluri Inc. has announced the successful regulatory registration of its subsidiary Cellav's regenerative aesthetics product, Regenativo+, in the UK. This registration supports the upcoming commercial launch in a market valued at approximately $900 million. The move is part of Pluri's broader strategy to expand its global footprint in regenerative aesthetics and longevity markets, following similar regulatory progress in the U.S.
Read more →Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%
Pluri Inc. Chairman Alejandro Weinstein has invested over $17 million, increasing his ownership to more than 30%. This investment reflects his confidence in Pluri's transition from development to commercial operations, particularly in longevity and tailored biologics. The company is experiencing strong interest from U.S. parties for potential collaborations and product purchases.
Read more →Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing
Pluri Inc. has announced the completion of U.S. cosmetic product listings for its regenerative aesthetic products, Regenativo+ and Placento+, through its subsidiary Cellav. The company is preparing for a commercial launch in the U.S. market, which is projected to grow significantly. Clinical validation supports the efficacy of the products, and discussions with distributors are underway. However, the products are not FDA approved and face regulatory requirements.
Read more →Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement
Pluri Inc. announced that Alejandro Weinstein, its Chairman, has made an additional $2.5 million investment at a 30% premium to market price. This follows a previous investment and highlights Weinstein's continued support for the company's growth strategy. The funds from this private placement, amounting to approximately $2.5 million, will be used for general working capital. The transaction involves the sale of common shares and warrants, with an emphasis on enhancing shareholder value through focused execution.
Read more →Pluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent
Pluri Inc. has been granted a patent by the China National Intellectual Property Administration for its 3D immune cell expansion and activation technology. This patent complements previously secured patents in the U.S., Japan, Korea, Australia, and Israel, strengthening Pluri's global intellectual property portfolio. The technology enables scalable and automated manufacturing of diverse immune cell therapies, positioning Pluri to capitalize on the rapidly growing cell therapy market in China. This strategic expansion is expected to support cross-border partnerships and global collaborations, contributing to the company's efforts in enhancing cost-efficiency and maintaining quality control in cell production.
Read more →Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials
Pluri, Inc. has announced the successful completion of the first phase of its program with Resbiomed Technologies, focusing on the production of placenta-derived biomaterials. The collaboration leverages Pluri's proprietary bioprocessing expertise to enhance the quality and scalability of these materials for use in regenerative medicine. Both companies are now prepared to advance to the next phase of the project, which aims to refine manufacturing processes and ensure consistent quality. This milestone underscores the increasing demand for PluriCDMO services in the biotech sector.
Read more →Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved
Pluri, Inc. has expanded its collaboration with Remedy Cell Ltd. by successfully implementing clinical-grade manufacturing processes at Pluri's GMP facility. This achievement includes the completion of engineering runs and the production of clinical-grade batches for Remedy Cell's initial Phase 1b clinical trial, marking significant progress in developing secretome-based therapies for fibrotic diseases. Both companies expressed optimism about their partnership as they aim to provide innovative biotherapeutic solutions to address unmet medical needs.
Read more →Pluri Appoints Alejandro Weinstein as Chairman of the Board to Lead Strategic Shift and Unlock Value, Backed by Additional Investment
Pluri Inc. has appointed Alejandro Weinstein as the new Chairman of the Board, signaling a strategic shift aimed at unlocking value within the company. Weinstein, one of Pluri's largest shareholders, plans to enhance market positioning and realize the potential of Pluri's assets. As part of the leadership transition, outgoing Chairman Zami Aberman will move to the role of Vice Chairman. Additionally, Pluri has entered a private placement agreement to raise approximately $2.5 million to support its operations.
Read more →Pluri and Subsidiaries Earn Multiple Industry Honors, Named as Overall BioAgriculture Company of the Year
Pluri Inc. has received multiple industry honors, including the title of Overall BioAgriculture Company of the Year from the Biotech Breakthrough Awards. Additionally, its subsidiaries Coffeesai Ltd. and Kokomodo Ltd. garnered significant recognition for innovations in sustainable food production and cellular agriculture technology, respectively. Pluri's CEO, Yaky Yanay, is set to accept the 2024 Egalitarian Employment Award on behalf of the company. These accolades highlight Pluri's strong position in the biotechnology sector and its commitment to developing impactful cell-based solutions.
Read more →Pluri Partners with Miss Universe Skincare Introducing Exosome-Enhanced Regenerative Skincare
Pluri Inc. has launched Cellav Health and Aesthetics Ltd., a wholly-owned subsidiary focused on regenerative skincare, following a partnership with Miss Universe Skincare. This collaboration aims to co-develop advanced skincare products utilizing Pluri's proprietary 3D cell expansion technology and is expected to launch its first product in 2026. The partnership is set to leverage Miss Universe Skincare's global distribution network, reaching a market projected to grow significantly in the coming years. This move aligns with Pluri's strategy to expand into high-demand, revenue-generating markets.
Read more →Leading Global Players Back and Fund Pluri’s Cell-Based Food and Agriculture Collaborations
Pluri, Inc. has entered significant collaborations across Asia, Europe, and the U.S. through its subsidiaries, aiming to innovate food and agriculture production with advanced cell expansion technologies. These partnerships are designed to enhance market presence in cultivated meat, cacao, and coffee industries, reflecting a growing demand for sustainable solutions. Each collaboration includes a proof-of-concept funded by global partners, indicating strong confidence in Pluri's technology.
Read more →Pluri Subsidiary Coffeesai and Instituto del Café de Chiapas Announce Strategic Collaboration to Advance Cell-Based Coffee Manufacturing in Mexico
Pluri Inc.'s subsidiary Coffeesai has partnered with the Instituto del Café de Chiapas to advance cell-based coffee manufacturing in Mexico. The collaboration outlines a three-phase roadmap focusing on cell line development, pilot-scale biofarming, and commercial-scale production. This initiative aims to leverage innovative biotechnology to create sustainable coffee solutions while addressing market demands and environmental challenges.
Read more →Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion
Pluri Inc. has reported significant growth in revenue, with nearly 400% increase in the first nine months of fiscal year 2025 compared to the previous year. The company is strategically entering the cultivated cacao and coffee markets, addressing global supply challenges. Additionally, Pluri is pursuing partnerships and has received further funding to support its initiatives in healthcare and AgTech. The CEO's letter emphasizes continued expansion efforts and the potential of its proprietary cell expansion technology.
Read more →